Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Releases Update to Glucocorticoid-Induced Osteoporosis Guideline

Ruth Jessen Hickman, MD  |  Issue: October 2023  |  October 10, 2023

The first anabolic treatment agent approved for osteoporosis was teriparatide. The parathyroid hormone recombinant analog mimics the normal physiological actions of parathyroid hormone to stimulate new bone formation.5 Parathyroid hormone-related protein is a structurally similar protein; since the ACR’s 2017 guideline, its analog, abaloparatide, has become available. Both are expensive and require daily injections, which some patients may find burdensome.

The first biologic agent approved to treat osteoporosis, denosumab, inhibits the transmembrane protein and secreted protein receptor activator of nuclear factor kappa-Β ligand (RANKL), which is required for the formation and survival of bone resorptive cells. A newer biologic agent, romosozumab, inhibits sclerostin, a protein released by osteocytes to reduce bone formation. Both are also much more expensive than bisphosphonates.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Selective estrogen receptor modulators (SERMs), such as raloxifene, originally developed to treat breast cancer, can also work as anti-resorptive agents via their action on bone cells.

Lifestyle Interventions

Lifestyle interventions are a key part of treatment for all patients with potential glucocorticoid-induced osteoporosis. Dr.Russell notes that tobacco and alcohol are both toxic to osteoblasts, so it’s important to provide tobacco cessation support and educate patients to use alcohol moderately.

Dr. Russell

Dr. Russell adds that, when appropriate, stopping or replacing medications that can be detrimental to bone can be helpful, such as replacing a proton pump inhibitor with a histamine-2 receptor blocker. “We also like to promote a robust weight-bearing program, whether it’s brisk walking or using the elliptical or light weights,” she adds.

It’s recommended that all patients on chronic glucocorticoid therapy (i.e., for three months or longer) adopt these lifestyle recommendations. Additionally, patients may need supplemental calcium and vitamin D to achieve optimal levels of these vitamins and minerals so critical for bone health.

Treatment

The 2017 guideline, which only considered fracture reduction as an indication of efficacy, recommended an oral bisphosphonate over other treatment options for patients over age 40 at moderate or high fracture risk, due to the drugs established safety, low cost and the lack of evidence that other agents provided better fracture reduction. Intravenous bisphosphonates, teriparatide, denosumab and raloxifene were recommended next, in that specific order.4

In the updated guideline, oral bisphosphonates are strongly recommended over no treatment in adults aged 40 or older at high or very high risk of glucocorticoid-induced osteoporotic fracture, based on strong data for efficacy and safety in this specific population.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesGlucocorticoid-Induced Osteoporosis

Related Articles

    Build Up Bone

    June 1, 2007

    Current management of osteoporosis

    Osteoporosis Experts Discuss Bisphosphonate Holidays

    November 24, 2020

    ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

    Unexpected Benefits of Bisphosphonates after Hip Fracture

    February 3, 2012

    Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

    Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

    October 13, 2015

    Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences